Cargando…

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia

BACKGROUND: Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Susanah, Susi, Idjradinata, Ponpon S., Sari, Nur M., Rakhmilla, Lulu E., Sribudiani, Yunia, Trisaputra, Jessica O., Moestopo, Octawyana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752293/ https://www.ncbi.nlm.nih.gov/pubmed/33415156 http://dx.doi.org/10.1155/2020/8185016

Ejemplares similares

Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive
por: Susanah, Susi, et al.
Publicado: (2021)

Serum TNF-α Level as a Possible Predictor of Inhibitor Levels in Severe Hemophilia A
por: Susanah, Susi, et al.
Publicado: (2021)

Extended family thalassemia screening as a feasible alternative method to be implemented in identifying carriers in West Java, Indonesia
por: Susanah, Susi, et al.
Publicado: (2021)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

The incidence and mortality of childhood acute lymphoblastic leukemia in Indonesia: A systematic review and meta-analysis
por: Garniasih, Dina, et al.
Publicado: (2022)

Allergic Reactions to E. coli Asparaginase are Associated with Decreased Asparaginase Activity in an Indonesian Pediatric Population with ALL
por: Sari, Nur Melani, et al.
Publicado: (2023)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Parental Factors Contribute to Childhood Cancer Abandonment Treatment During COVID-19
por: Susanah, Susi, et al.
Publicado: (2022)

Acute Lower Respiratory Infection Profile in Children at Tertiary Hospital Bandung: Is There a Difference Before and During COVID-19 Pandemic?
por: Majeda, Allisa, et al.
Publicado: (2022)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Prospective changes of cardiac iron and function by MR in pediatric thalassemia major patients treated with different chelators or not chelated
por: Meloni, Antonella, et al.
Publicado: (2015)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia
por: Reddy, Paavani S., et al.
Publicado: (2022)

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia
por: Reisi, Nahid, et al.
Publicado: (2022)

Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients
por: Chawsamtong, Sriwatree, et al.
Publicado: (2022)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
por: Nuzzi, Raffaele, et al.
Publicado: (2021)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Renal function in β-thalassemia major patients treated with two different iron-chelation regimes
por: Tanous, Osama, et al.
Publicado: (2021)

Beliefs about chelation among thalassemia patients
por: Trachtenberg, Felicia L, et al.
Publicado: (2012)

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy
por: Farmaki, Kallistheni, et al.
Publicado: (2008)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
por: Seyedifar, Meysam, et al.
Publicado: (2016)

A Multicenter ICET-A Study on Age at Menarche and Menstrual Cycles in Patients with Transfusion-Dependent Thalassemia (TDT) who Started Early Chelation Therapy with Different Chelating Agents
por: Di Maio, Salvatore, et al.
Publicado: (2023)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Synergy of Iron Chelators and Therapeutic Peptide Sequences Delivered via a Magnetic Nanocarrier
por: Abayaweera, Gayani S., et al.
Publicado: (2017)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fk0655p50k499smnacplm8u05e